Related references
Note: Only part of the references are listed.Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study
Salomon Tendler et al.
ACTA ONCOLOGICA (2020)
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Hyun Cheol Chung et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer
Christine M. Cramer-van der Welle et al.
EUROPEAN JOURNAL OF CANCER CARE (2020)
Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
Ticiana Leal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (vol 33, pg 853, 2018)
Matthew D. Hellmann et al.
CANCER CELL (2019)
Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials
Shrinivas Rathod et al.
EUROPEAN JOURNAL OF CANCER (2019)
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
Biagio Ricciuti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study
Claus-Christoph Steffens et al.
LUNG CANCER (2019)
Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer
Daisy W. S. Mak et al.
EUROPEAN JOURNAL OF CANCER (2019)
Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review
Thomopoulou Konstantina et al.
LUNG CANCER (2019)
IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
M. Reck et al.
ANNALS OF ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
The Role of Prophylactic Cranial Irradiation in Patients With Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chi Hoon Maeng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Shirish M. Gadgeel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Do immune checkpoint inhibitors need new studies methodology?
Roberto Ferrara et al.
JOURNAL OF THORACIC DISEASE (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
M Reck et al.
ANNALS OF ONCOLOGY (2018)
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Marcello Tiseo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
Francesco Facchinetti et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
PD-L1 expression in small cell neuroendocrine carcinomas
Anne M. Schultheis et al.
EUROPEAN JOURNAL OF CANCER (2015)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Small-cell lung cancer
Jan P. van Meerbeeck et al.
LANCET (2011)
Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis
Antonio Rossi et al.
LUNG CANCER (2010)
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Lorraine C. Pelosof et al.
MAYO CLINIC PROCEEDINGS (2010)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R. Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Neurologic disorders in 432 consecutive patients with small cell lung carcinoma
T Seute et al.
CANCER (2004)
Share Paper
